The global Heart Pump Device market was worth around USD 1983.10 billion in 2021 and is estimated to grow to about USD 6162.34 billion by 2028, with a compound annual growth rate (CAGR) of approximately 20.80 percent over the forecast period.
Industry Prospective:
The global Heart Pump Device market was worth around USD 1983.10 billion in 2021 and is estimated to grow to about USD 6162.34 billion by 2028, with a compound annual growth rate (CAGR) of approximately 20.80 percent over the forecast period. The report analyzes the Heart Pump Device market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Heart Pump Device market.
Heart Pump Device Market: Overview
Heart failure occurs when the heart is unable to pump enough blood to meet the body's requirements. This syndrome could be caused by coronary artery disease, such as a recent myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, and other factors. Many different types of heart pump devices are available on the market to assist cardiac circulation, depending on the cardiovascular disease. They are surgically implanted and used to provide temporary or long-term support for heart function in persons who have a weak heart or erratic blood flow. Several people may benefit from heart pump devices as a treatment alternative for mechanical circulatory assistance.
The rise in the prevalence of cardiovascular illnesses, the increase in the elderly population, and the increase in new product advancements by industry participants are all driving the global heart pump device market forward. Due to a scarcity of heart donors, heart pump devices serve as a viable alternative, fueling the global market's expansion. During the projection period, however, constraints such as the high cost of heart pump devices and the poor reimbursement situation in developing countries are projected to limit market growth. Furthermore, the market's growth is hampered by turbulence and high shear stresses associated with mechanical heart valves (MHVs), as well as the need for patients to take constant anti-coagulation therapy.
COVID-19 Impact:
Following the global epidemic of COVID-19, there have been considerable changes in the healthcare system. Several countries have agreed to postpone elective surgery in the cardiac care industry to reduce the risk of infection. Elective cardiac procedures have been postponed in the UK because to the impact of COVID19 on healthcare systems. HF admissions were dramatically reduced during the lockdown, according to a study done across eight Italian hospitals from February 21 to March 31, 2020. HF patients may have died at home without seeking medical attention during the COVID19 lockdown in some situations.With fewer HF hospitalizations, the market for heart pump devices is expected to fall significantly in 2020. Similarly, the breakout of COVID-19 has resulted in a drop in revenue for market players. According to Abiomed's 10-k form, revenues from Impella pump sales were impacted in the fourth quarter of FY 2020 due to low patient utilisation as a result of fewer patient visits. COVID-19 reduced Impella's revenue by around USD 17 million, largely in the United States and Europe. The FDA has granted emergency use authorisation (EUA) to firms that manufacture ventricular assist devices to treat COVID patients with right heart failure or decompensation, including pulmonary embolism, as a result of the COVID epidemic (PE).Abiomed got an EUA from the FDA in August 2020 for the left-sided Impella heart pumps, which offer left ventricular unloading and support COVID-19 patients on ECMO. Impella RP also got an EUA from the FDA, allowing it to be used in patients with COVID-19-related right heart failure or decompensation. These advancements aided the company's significant expansion.
Heart Pump Device Market: Growth Drivers
Long waiting periods for heart transplant procedures to drive global market growth
Due to the rising incidence of CVDs and heart failure in recent years, the demand for heart transplantation has increased dramatically. However, a global shortage of suitable hearts for transplantation has developed from the inability to meet current demand. As of March 2018, there were around 3,980 candidates on the heart transplant waiting list, according to the national database kept by the Health Resources and Services Administration (US). Significant disparities in the number of donors and patients on waiting lists have been seen even at the country level. In Australia, for example, around 1,650 people were on the waiting list for a heart transplant in 2020, but only 463 donors were available (Source: Transplant Australia Ltd).According to the Transplant Activity Report 2018/19, the number of patients on heart transplant waiting lists had climbed by 134% since 2010. In this situation, not only has the number of patients on the transplant waiting list increased, but so has the number of patients who have died while on the waiting list. As a bridge-to-transplantation (BTT) or destination therapy for advanced HF, LVADs have become crucial tools (DT). The expanding number of end-stage HF patients, combined with technological advancements in mechanical circulatory support (MCS), has raised demand for MCS devices used in these patients. Between 2009 and 2016, MCS, LVAD, RVAD, TAH, and ECMO were used to bridge 43 percent of beneficiaries. These devices give patients with the required support while they wait for a heart transplant or as a long-term option for those who are not candidates for a heart transplant. As a result of the considerable gap between demand and supply of donor hearts, the heart pump devices market is likely to rise in the future years.
Heart Pump Device Market: Restraints
High cost of heart pump device equipment in Heart Pump Devices to hamper the market growth
For bridge-to-heart transplantation, ventricular support devices, notably left ventricular assist devices (LVADs), are commonly employed. Although LVADs are considered life-saving devices, they do come with a number of drawbacks. By six months after implantation, up to 60% of patients have experienced LVAD-related problems. Nearly 80% of patients had at least one adverse event after two years. Readmissions to the hospital that were not scheduled are common. Patients are readmitted on average 2.2 times over the course of their 11-month median follow-up period. Device thrombosis, bleeding issues, renal impairment, ischemic and hemorrhagic strokes, multi-organ failure, and infections are all major non-surgical adverse events and consequences linked with LVAD. If left untreated, certain problems can be fatal to the victims.
Heart Pump Device Market: Opportunities
Development of non-invasive, portable, and advanced fetal monitors to bring growth opportunities for global market
Various companies with items in the development phase make up the devices market. Companies with products in the pipeline concentrate on finding unique solutions that will help the market grow faster. For example, the TAH industry is a fast-paced area of device development that is expected to have a rise in launches and approvals in the future years. When compared to the SynCardia Total Heart (sole player until December 2020), these TAHs offer more sophisticated functions, making them a better alternative in the future. CARMAT's entire artificial heart, for example, got the CE Mark in December 2020. CARMAT's TAH is self-regulating, changing blood flow in response to the patient's physical activity.
Global Heart Pump Device Market: Segmentation
The global Heart Pump Device market is segregated based on product ,type,therapy and region.
The heart pump devices market is divided into three categories based on products: ventricular assist devices, intra-aortic balloon pumps, and whole artificial hearts. The largest and fastest-growing segment of this market is ventricular assist devices. Technological developments, a scarcity of organ donors, and an increase in the global prevalence of heart failure are all contributing to this segment's growth.
The market is divided into implanted heart pump devices and extracorporeal heart pump devices based on type. Due to the introduction of innovative products by major players and the increased need for an efficient solution to manage heart failure, implantable heart pump devices will account for the highest share of this market by 2020.
The market is divided into bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination treatment (DT), and other therapies, depending on the therapy. The BTT segment held the greatest proportion of this market in 2020. The rise is the segment is due to the availability of VADs for BTT and increased awareness of transplantation
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Recent Developments
Regional Landscape
The market for heart pump devices is dominated by the Americas, owing to an increase in the frequency of cardiovascular disorders and an ageing population. Moreover, the government's increased initiatives, as well as funding for research & development in innovative medical treatment alternatives, will fuel the expansion of the heart pump devices market in the region throughout the forecast period. Due to an increase in the frequency of chronic cardiovascular illnesses and rising healthcare costs, Asia-Pacific is expected to see considerable growth in the heart pump devices market. Furthermore, the region's improving standard of living is expected to fuel the expansion of the heart pump devices market in the future years.
Competitive Landscape
Some of the main competitors dominating the global Heart Pump Device market include - Abbott Laboratories (US), Abiomed (US), Medtronic (Ireland), Teleflex Incorporated (US), SynCardia Systems (US), Fresenius Medical Care AG & Co. KGaA (Germany), Getinge (Sweden), CardiacAssist, Inc. (US), Berlin Heart (Germany), Jarvik Heart, Inc. (US), CARMAT (France), SENKO MEDICAL INSTRUMENT Mfg. CO., LTD. (Japan), Angiodroid (Italy), CardioDyme (US), and World Heart Corporation (US).
Global Heart Pump Device market is segmented as follows:
By Product
By Type
By Therapy
By Region
Heart pumps are implantable medical devices that are electromechanical in nature, which are used in cases of treating a dysfunctioning heart or heart failures. These pumps help to improve heart functioning and blood circulation. They are implanted in either one of the ventricles of the heart or in both the ventricles. This increases myocardial oxygen perfusion and cardiac output simultaneously. Increasing prevalence of cardiovascular diseases is one of the major factors fuelling the expansion of the heart pump device market. Cardiovascular diseases (CVDs) are among the leading causes of death worldwide. According to the WHO, in 2015, about 17.7 million population died due to cardiovascular diseases globally. Among them, 6.7 million people died because of stroke and 7.4 million people died because of coronary heart disease. Thus, the rising number of heart diseases and cases of heart failures is expected to further drive the heart pump device market growth in the forecast timeframe.
The global heart pump device market is divided based on product, therapy, type, and geography. On the basis of product, the heart pump device market is divided into the total artificial heart,intra-aortic balloon pumps, and ventricular assist devices. Ventricular assist devices segment is further sub-segmented into bi-ventricular assist devices, percutaneous ventricular assist devices, right ventricular assist devices, and left ventricular assist devices. Considering the product segment, ventricular assist devices accounted for a major share in the heart pump device market, owing to a high number of device implantations in the left ventricle of the heart as it is the major pumping point. By type, the market for heart pump device is categorized into extracorporeal heart pump devices and implantable heart pump devices. The therapy segment is bifurcated into Bridge-To-Candidacy (BTC), Bridge-To-Transplant (BTT), Destination Therapy (DT), and other therapies.
Based on region, North America held a dominant share of the global market for heart pump device in 2017 and is anticipated to continue its dominance over the forthcoming years as well. High incidences of cardiovascular diseases, advanced healthcare facilities, currently available treatment options, and the favorable regulatory scenario will drive the heart pump device market in the forecast timeframe in this region. Europe is estimated to hold the second largest share in the global heart pump device market. The Asia Pacific heart pump device market is expected to record the highest CAGR in the forecast timeframe, owing to increasing heart surgeries, rising disposable income, changing lifestyles, and increasing awareness about CVD among the population of the region. Moreover, increasing research and development expenditure and rising number of population with high obesity and high blood pressure are expected to propel the development of the heart pump device market in the Asia Pacific region.
Some key players of the heart pump device market are Abbott Laboratories, SynCardia Systems, Abiomed, Fresenius Medical Care Medtronic, Jarvik Heart, Getinge, Teleflex, Reliantheart, CardiacAssist, Terumo, and Berlin Heart. Currently, the market growth rate is very high, which has encouraged the leading players to focus on consolidation through product licensing and long-term partnerships in order to gain maximum share in the heart pump device market.
Request the coronavirus impact analysis across industries and markets
The need for heart pump devices is being driven by an increase in the prevalence of cardiovascular disorders, an increase in the number of regulatory approvals, and a large gap between the demand and availability of donor hearts. The rising reliance on ventricular assist devices for the treatment of heart failure, as well as technological improvements to improve the safety of these devices, are driving the ventricular assist devices market. During the projection period, the high cost of devices and implantation procedures, as well as the poor reimbursement situation in developing countries, are projected to limit the market's growth.
According to the Market Research report, the global Heart Pump Device market was worth about 1983.10 (USD billion) in 2021 and is predicted to grow to around 6162.34 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 20.80 percent.
Due to an increase in the prevalence of cardiovascular illnesses and an ageing population, the Americas dominate the market for heart pump devices. Furthermore, the government's increasing initiatives, as well as financing for research and development in breakthrough medical treatment alternatives, will propel the heart pump devices market in the region to new heights over the forecast period. Asia-Pacific is predicted to witness significant growth in the heart pump devices market due to an increase in the prevalence of chronic cardiovascular disorders and growing healthcare costs. In addition, the growing standard of living in the region is likely to boost the growth of the heart pump devices market in the coming years.
Some of the main competitors dominating the global Heart Pump Device market include - Abbott Laboratories (US), Abiomed (US), Medtronic (Ireland), Teleflex Incorporated (US), SynCardia Systems (US), Fresenius Medical Care AG & Co. KGaA (Germany), Getinge (Sweden), CardiacAssist, Inc. (US), Berlin Heart (Germany), Jarvik Heart, Inc. (US), CARMAT (France), SENKO MEDICAL INSTRUMENT Mfg. CO., LTD. (Japan), Angiodroid (Italy), CardioDyme (US), and World Heart Corporation (US).
Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No 020-46277770
US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed